MRVI Investors Have the Opportunity to Lead the Maravai LifeSciences Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning revenue recognition and internal controls [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Maravai and its executives made false or misleading statements and failed to disclose inadequate internal controls over financial reporting related to revenue recognition [4]. - Maravai identified an error in revenue recognition that resulted in approximately $3.9 million being recorded incorrectly, leading to a material weakness in its internal controls [5]. - Following the announcement of these issues, Maravai's share price fell by$0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [6]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding$50,000 between August 7, 2024, and February 24, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1]. - There is a deadline of May 5, 2025, for investors to seek the role of lead plaintiff in the federal securities class action filed against Maravai [2][7]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Maravai's conduct [8].